{"id":80976,"date":"2025-08-12T21:37:01","date_gmt":"2025-08-12T21:37:01","guid":{"rendered":"https:\/\/www.merckconnect.ca\/fr\/?post_type=mhh-sticky-footer&#038;p=80976"},"modified":"2026-06-11T07:26:05","modified_gmt":"2026-06-11T07:26:05","slug":"80976","status":"publish","type":"mhh-sticky-footer","link":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/","title":{"rendered":"DELSTRIGO-PIFELTRO"},"content":{"rendered":"<div class=\"mhh-sticky-footer-panel mhh-sticky-footer-panel--05f33a7439a5aa7ecfd61d74104ac577\">\n    <button class=\"mhh-sticky-footer-panel__expand-button\" \n            data-event-name=\"accordion_click\" \n            data-design-module=\"indication\"\n            data-design-category=\"accordion\"\n            data-design-label=\"expand\">\n                    <svg\n            xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n            fill=\"currentColor\"\n            viewBox=\"0 0 16 16\"\n            >\n            <path\n            d=\"M8 4a.5.5 0 0 1 .5.5v3h3a.5.5 0 0 1 0 1h-3v3a.5.5 0 0 1-1 0v-3h-3a.5.5 0 0 1 0-1h3v-3A.5.5 0 0 1 8 4z\"\/>\n            <\/svg>\n                <span>EXPAND<\/span>\n        <\/button>\n    <div class=\"mhh-sticky-footer-inner\">\n    \n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--093c91d2133fd2cbae7bf753da791a74\"><a href=\"https:\/\/www.merck.ca\/fr\/wp-content\/uploads\/sites\/83\/2021\/07\/DELSTRIGO-PM_F.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Monographie de DELSTRIGO\u00ae<\/a><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--207b3ab4b553d1f81e71a41ba674b1f8\"><a href=\"https:\/\/www.merck.ca\/fr\/wp-content\/uploads\/sites\/83\/2021\/07\/PIFELTRO-PM_F.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Monographie de PIFELTRO\u00ae<\/a><\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color wp-elements-03b10f91143d88e9ebecc34c428ac87b mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--30e964b6ac14f1e7692fdae080f3e062\" style=\"background-color:#12b7c1\"><strong>RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9<\/strong><\/p>\n\n    <\/div>\n<\/div>\n\n\n<div class=\"mhh-sticky-footer-expanded-panel mhh-sticky-footer-expanded-panel--f50bf3832e14000c7dbe72662d79e6cc \" dir=\"ltr\">\n    <div class=\"mhh-sticky-footer-expanded-panel__inner\">\n        <div class=\"mhh-sticky-footer-expanded-panel__close-button-wrapper\">\n            <button class=\"mhh-sticky-footer-expanded-panel__close-button\">\n                        <svg\n                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                fill=\"currentColor\"\n                viewBox=\"0 0 16 16\"\n            >\n                <path\n                d=\"M4.646 4.646a.5.5 0 0 1 .708 0L8 7.293l2.646-2.647a.5.5 0 0 1 .708.708L8.707 8l2.647 2.646a.5.5 0 0 1-.708.708L8 8.707l-2.646 2.647a.5.5 0 0 1-.708-.708L7.293 8 4.646 5.354a.5.5 0 0 1 0-.708z\"\/>\n            <\/svg>\n                                    <\/button>\n        <\/div>\n        <div class=\"mhh-sticky-footer-expanded-panel__body\">\n            \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color wp-elements-91d56c0ec168519281753983774381ab mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8d0f33acef86f50ac46ba41689218bd7\" style=\"background-color:#12b7c1\"><strong>RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9<\/strong><\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--00b585c2522127bdbaa2af802de811ef mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--c7bb2055f7ff23997762a7d9bd08fda6 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color has-text-color has-link-color has-object-object-font-size wp-elements-08b0e8b7887632503bbd4468cf2932f9   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--31cbce84946b0adb85abb3213792cb34\" style=\"color:#c0581a\"><strong>RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9 DE DELSTRIGO\u00ae<\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--40630a786e99abbd127e2e42e73ef596\"><span style=\"text-decoration: underline\">I<strong>ndications et usage clinique :<\/strong><br><\/span>DELSTRIGO\u00ae (doravirine, lamivudine et fumarate de t\u00e9nofovir disoproxil) est indiqu\u00e9 comme traitement complet contre l\u2019infection par le virus de l\u2019immunod\u00e9ficience humaine de type 1 (VIH-1) chez les adultes et les enfants \u00e2g\u00e9s de <span class=\"no-text-breaking\">12 ans<\/span> et plus et pesant au moins <span class=\"no-text-breaking\">35 kg<\/span> qui ne pr\u00e9sentent pas d\u2019ant\u00e9c\u00e9dents ou de signes d\u2019une r\u00e9sistance virale \u00e0 la doravirine, \u00e0 la lamivudine ou au t\u00e9nofovir. L\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de DELSTRIGO\u00ae n\u2019ont pas \u00e9t\u00e9 \u00e9tablies chez les patients de moins de <span class=\"no-text-breaking\">12 ans<\/span> et pesant moins de <span class=\"no-text-breaking\">35 kg.<\/span> Les donn\u00e9es disponibles chez les patients \u00e2g\u00e9s de <span class=\"no-text-breaking\">65 ans<\/span> et plus sont peu nombreuses.<br><br><strong><u>Contre-indications :<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--67c9a46933589a5f94d11de4b4d0a627 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Utilisation avec des m\u00e9dicaments qui sont de puissants inducteurs de l\u2019enzyme\u00a0CYP3A, y compris, mais sans s\u2019y limiter, la carbamaz\u00e9pine, l\u2019oxcarbaz\u00e9pine, le ph\u00e9nobarbital et la ph\u00e9nyto\u00efne (anticonvulsants); l\u2019enzalutamide (inhibiteur des r\u00e9cepteurs des androg\u00e8nes); la rifampine et la rifapentine (antimycobact\u00e9riens); le mitotane (agent cytotoxique); et le millepertuis (<em>Hypericum perforatum<\/em>).    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d597b1a772c169a092c9ff9408668b01\"><strong><u>Mises en garde et pr\u00e9cautions les plus importantes :<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--0e663c9f414b99559e2692bef37a2321 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Infection chronique par le virus de l\u2019h\u00e9patite\u00a0B <\/strong><span class=\"no-text-breaking\"><strong>(VHB)\u00a0:<\/strong> <\/span>N\u2019est pas approuv\u00e9 pour le traitement de l\u2019infection chronique par le VHB; son innocuit\u00e9 et son efficacit\u00e9 n\u2019ont pas \u00e9t\u00e9 \u00e9tablies chez les patients co-infect\u00e9s. Des exacerbations aigu\u00ebs graves du VHB ont \u00e9t\u00e9 rapport\u00e9es chez des patients co-infect\u00e9s par le VHB et le <span class=\"no-text-breaking\">VIH-1<\/span> et qui ont cess\u00e9 de prendre la lamivudine ou le fumarate de t\u00e9nofovir disoproxil, deux des composants de DELSTRIGO\u00ae. Une surveillance \u00e9troite au moyen d\u2019examens cliniques et d\u2019analyses de laboratoire pendant au moins plusieurs mois s\u2019impose apr\u00e8s l\u2019arr\u00eat du traitement. Selon le cas, instaurer un traitement anti-h\u00e9patite\u00a0B, notamment chez les patients atteints d\u2019une maladie h\u00e9patique avanc\u00e9e ou de cirrhose, car l\u2019exacerbation de l\u2019h\u00e9patite apr\u00e8s le traitement peut entra\u00eener une d\u00e9compensation et une insuffisance h\u00e9patiques.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>N\u00e9phrotoxicit\u00e9 :  <\/strong>Des cas d\u2019insuffisance r\u00e9nale, y compris d\u2019insuffisance r\u00e9nale aigu\u00eb et de syndrome de Fanconi, ont \u00e9t\u00e9 rapport\u00e9s avec l\u2019utilisation du fumarate de t\u00e9nofovir disoproxil.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Allaitement : <\/strong>Les m\u00e8res ne doivent pas allaiter si elles re\u00e7oivent DELSTRIGO\u00ae.    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--08efcbb19de16c397bd39112f9e8d80c\"><strong><u>Autres mises en garde et pr\u00e9cautions <\/u><span class=\"no-text-breaking\"><u>pertinentes<\/u> :<\/span><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--87805062614b512f07e156e5ef4fe1b8 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Ne pas administrer avec d\u2019autres antir\u00e9troviraux, avec de l\u2019ad\u00e9fovir dipivoxil ou avec de la doravirine en monoth\u00e9rapie \u00e0 moins qu\u2019un ajustement de la dose de doravirine soit n\u00e9cessaire.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    N\u2019a pas \u00e9t\u00e9 \u00e9valu\u00e9 chez les patients ayant des ant\u00e9c\u00e9dents d\u2019\u00e9chec virologique avec d\u2019autres antir\u00e9troviraux.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Ne doit pas \u00eatre administr\u00e9 aux patients qui ont d\u00e9j\u00e0 suivi un traitement antir\u00e9troviral et qui pr\u00e9sentent des mutations associ\u00e9es \u00e0 une r\u00e9sistance \u00e0 la doravirine, \u00e0 la lamivudine ou au t\u00e9nofovir, ou une r\u00e9sistance soup\u00e7onn\u00e9e \u00e0 la doravirine, \u00e0 la lamivudine ou au t\u00e9nofovir si aucun g\u00e9notype n\u2019est fourni.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Une perte osseuse et des anomalies de la min\u00e9ralisation sont associ\u00e9es au fumarate de t\u00e9nofovir disoproxil.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    \u00c9viter de conduire et d\u2019utiliser des machines en cas de fatigue, d\u2019\u00e9tourdissement et de somnolence.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    \u00c9viter l\u2019utilisation concomitante d\u2019inducteurs mod\u00e9r\u00e9s du CYP3A. Si l\u2019administration concomitante ne peut \u00eatre \u00e9vit\u00e9e, prendre un comprim\u00e9 de doravirine \u00e0 <span class=\"no-text-breaking\">100 mg (PIFELTRO\u00ae)<\/span> environ 12 heures apr\u00e8s la dose de DELSTRIGO\u00ae.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    L\u2019exposition au fumarate de t\u00e9nofovir disoproxil augmente lorsqu\u2019il est utilis\u00e9 avec certains protocoles de traitement contre le virus de l\u2019h\u00e9patite C.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Envisager l\u2019\u00e9valuation du taux s\u00e9rique de lipides et de la glyc\u00e9mie.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    De tr\u00e8s rares cas d\u2019aplasie pure des globules rouges ont \u00e9t\u00e9 signal\u00e9s lors de l\u2019utilisation de la lamivudine.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Des cas d\u2019acidose lactique et d\u2019h\u00e9patom\u00e9galie grave avec st\u00e9atose, y compris des cas mortels, ont \u00e9t\u00e9 signal\u00e9s.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Syndrome inflammatoire de reconstitution immunitaire.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Des cas d\u2019angi\u0153d\u00e8me chez les patients trait\u00e9s avec le fumarate de t\u00e9nofovir disoproxil ont \u00e9t\u00e9 signal\u00e9s.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Apparition ou aggravation d\u2019une insuffisance r\u00e9nale avec l\u2019utilisation du fumarate de t\u00e9nofovir disoproxil.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Les m\u00e9decins sont invit\u00e9s \u00e0 d\u00e9clarer les cas de grossesse en vue de leur ajout au registre d\u2019exposition \u00e0 des antir\u00e9troviraux pendant la grossesse au <a href=\"http:\/\/www.apregistry.com\/.\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/www.apregistry.com\/<\/a>.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    R\u00e9actions cutan\u00e9es, y compris des cas de n\u00e9crolyse \u00e9pidermique toxique.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Des soins particuliers sont conseill\u00e9s chez les patients \u00e2g\u00e9s de 65\u00a0ans et plus en raison de changements associ\u00e9s \u00e0 l\u2019\u00e2ge, tels que la diminution de la fonction r\u00e9nale.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Non recommand\u00e9 chez les patients dont la clairance de la cr\u00e9atinine estim\u00e9e est &lt; 50 mL\/min.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    N\u2019a pas \u00e9t\u00e9 \u00e9tudi\u00e9 chez les patients atteints d\u2019insuffisance h\u00e9patique grave; la prudence est donc conseill\u00e9e.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Apparition de variantes du VHB r\u00e9sistantes \u00e0 la lamivudine.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Les patients co-infect\u00e9s par le VIH-1 et le VHB ou le VHC ont un risque accru de pr\u00e9senter des effets ind\u00e9sirables h\u00e9patiques s\u00e9v\u00e8res.    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color  has-link-color mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--aa4ed68d67fca1c439e517eb1aa959d2\"><strong><span style=\"text-decoration: underline\">Pour obtenir de plus amples renseignements<\/span> :<br><\/strong>Veuillez consulter la <a href=\"https:\/\/www.merck.ca\/fr\/wp-content\/uploads\/sites\/83\/2021\/07\/DELSTRIGO-PM_F.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">monographie du produit<\/a> pour obtenir des renseignements importants sur les contre-indications, les mises en garde, les pr\u00e9cautions, les effets ind\u00e9sirables, les interactions m\u00e9dicamenteuses et la posologie, lesquels n\u2019ont pas \u00e9t\u00e9 abord\u00e9s dans le pr\u00e9sent document. Il est \u00e9galement possible d\u2019obtenir cette monographie en appelant au <span class=\"no-text-breaking\">1 800 567-2594.<\/span><br><br><br><strong>R\u00e9f\u00e9rence&nbsp;:<\/strong> Monographie de DELSTRIGO\u00ae. Merck Canada Inc. <span class=\"no-text-breaking\">23 septembre 2025.<\/span><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--a417f69cd466fba5d9c054441989966d mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-border-color has-has-red-border-color-border-color has-text-color has-link-color has-object-object-font-size wp-elements-2b0e6804be1fc9daef0df68e7cb474d5   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--73249098733bfe64471e5c430d16f2d0\" style=\"color:#12b7c1\"><strong>RENSEIGNEMENTS IMPORTANTS SUR L\u2019INNOCUIT\u00c9 DE PIFELTRO\u00ae<\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d62cd50e74ac2669c15f83dfeee4367e\"><strong><span style=\"text-decoration: underline\">Indications et usage clinique :<\/span><br><\/strong>PIFELTRO\u00ae (doravirine) est indiqu\u00e9, en association avec d\u2019autres antir\u00e9troviraux, pour le traitement de l\u2019infection par le VIH-1 chez les adultes et les enfants de <span class=\"no-text-breaking\">12&nbsp;ans<\/span> et plus pesant au moins <span class=\"no-text-breaking\">35&nbsp;kg<\/span> qui ne pr\u00e9sentent pas d\u2019ant\u00e9c\u00e9dents ou de signes d\u2019une r\u00e9sistance virale \u00e0 la doravirine. L\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de PIFELTRO\u00ae ont \u00e9t\u00e9 \u00e9tablies chez les enfants \u00e2g\u00e9s de <span class=\"no-text-breaking\">\u2265 12 ans<\/span> et pesant au moins <span class=\"no-text-breaking\">35 kg<\/span> recevant la doravirine \u00e0 <span class=\"no-text-breaking\">100 mg<\/span> une fois par jour. L\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de PIFELTRO\u00ae n\u2019ont pas \u00e9t\u00e9 \u00e9tablies chez les patients de moins de <span class=\"no-text-breaking\">12 ans<\/span> pesant moins de <span class=\"no-text-breaking\">35 kg<\/span>. Les donn\u00e9es disponibles sur l\u2019utilisation de la doravirine chez les patients \u00e2g\u00e9s de <span class=\"no-text-breaking\">65 ans<\/span> et plus sont peu nombreuses.<br><strong><u><br>Contre-indications&nbsp;:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--67c9a46933589a5f94d11de4b4d0a627 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Utilisation avec des m\u00e9dicaments qui sont de puissants inducteurs de l\u2019enzyme\u00a0CYP3A, y compris, mais sans s\u2019y limiter, la carbamaz\u00e9pine, l\u2019oxcarbaz\u00e9pine, le ph\u00e9nobarbital et la ph\u00e9nyto\u00efne (anticonvulsants); l\u2019enzalutamide (inhibiteur des r\u00e9cepteurs des androg\u00e8nes); la rifampine et la rifapentine (antimycobact\u00e9riens); le mitotane (agent cytotoxique); et le millepertuis (<em>Hypericum perforatum<\/em>).    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d597b1a772c169a092c9ff9408668b01\"><strong><u>Mises en garde et pr\u00e9cautions les plus importantes :<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--055faae0e309129a04521b6804881e15 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Allaitement\u00a0:<\/strong> Les m\u00e8res ne doivent pas allaiter si elles re\u00e7oivent PIFELTRO\u00ae.    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--966c8a690f2461da2f10b832d543bbb2\"><strong><u>Autres mises en garde et pr\u00e9cautions <span class=\"no-text-breaking\">pertinentes :<\/span><\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--6185ab0418d6f01e99882877dbad8397 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    N\u2019a pas \u00e9t\u00e9 \u00e9valu\u00e9 chez les patients ayant des ant\u00e9c\u00e9dents d\u2019\u00e9chec virologique avec d\u2019autres antir\u00e9troviraux.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Ne doit pas \u00eatre administr\u00e9 aux patients qui ont d\u00e9j\u00e0 re\u00e7u un traitement antir\u00e9troviral et qui pr\u00e9sentent des mutations associ\u00e9es \u00e0 une r\u00e9sistance aux INNTI pouvant conf\u00e9rer une r\u00e9sistance \u00e0 la doravirine, ni aux patients qui pr\u00e9sentent une suppression virologique et une r\u00e9sistance soup\u00e7onn\u00e9e aux INNTI si aucun g\u00e9notype n\u2019est fourni.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    \u00c9viter de conduire et d\u2019utiliser des machines en cas de fatigue, d\u2019\u00e9tourdissement et de somnolence.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    La prudence est recommand\u00e9e lorsque PIFELTRO\u00ae est prescrit avec des m\u00e9dicaments qui peuvent r\u00e9duire l\u2019exposition \u00e0 la doravirine.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Envisager l\u2019\u00e9valuation du taux s\u00e9rique de lipides et de la glyc\u00e9mie.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Syndrome inflammatoire de reconstitution immunitaire.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Les m\u00e9decins sont invit\u00e9s \u00e0 d\u00e9clarer les cas de grossesse en vue de leur ajout au registre d\u2019exposition \u00e0 des antir\u00e9troviraux pendant la grossesse au <a href=\"http:\/\/www.apregistry.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/www.apregistry.com\/<\/a>.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n     R\u00e9actions cutan\u00e9es, y compris des cas de n\u00e9crolyse \u00e9pidermique toxique.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    N\u2019a pas \u00e9t\u00e9 \u00e9tudi\u00e9 chez les patients atteints d\u2019une maladie r\u00e9nale au stade terminal ou qui sont sous dialyse.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    N\u2019a pas \u00e9t\u00e9 \u00e9tudi\u00e9 chez les patients atteints d\u2019insuffisance h\u00e9patique grave.    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color  has-link-color mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--40df42cd405309096a84fa4bd699b8ef\"><strong><span style=\"text-decoration: underline\">Pour de plus amples renseignements<\/span> :<br><\/strong>Veuillez consulter la <a href=\"https:\/\/www.merck.ca\/fr\/wp-content\/uploads\/sites\/83\/2021\/07\/PIFELTRO-PM_F.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">monographie du produit<\/a> pour obtenir des renseignements importants sur les contre-indications, les mises en garde, les pr\u00e9cautions, les effets ind\u00e9sirables, les interactions m\u00e9dicamenteuses et la posologie, lesquels n\u2019ont pas \u00e9t\u00e9 abord\u00e9s dans le pr\u00e9sent document. Il est \u00e9galement possible d\u2019obtenir cette monographie en appelant au <span class=\"no-text-breaking\">1 800 567-2594.<\/span><br><br><br><strong>R\u00e9f\u00e9rence&nbsp;:<\/strong> Monographie de PIFELTRO\u00ae. Merck Canada Inc., <span class=\"no-text-breaking\">23&nbsp;septembre&nbsp;2025.<\/span><br><\/p>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ae12ebeab98e1928ab265a9435e46b4e\">CYP3A = cytochrome P450, famille 3,<span class=\"no-text-breaking\"> sous-famille A;<\/span> INNTI = inhibiteur non nucl\u00e9osidique de la transcriptase inverse; TDF = fumarate de t\u00e9nofovir disoproxil; VHB = virus de l\u2019h\u00e9patite B; VHC = virus de l\u2019h\u00e9patite C; VIH = virus de l\u2019immunod\u00e9ficience humaine.<\/p>\n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"mhh-sticky-footer-safety-content\">\n    <\/div>\n","protected":false},"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"0","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"promomats_ca_generated_at":0,"promomats_ca_screen_sizes":["Desktop","Mobile"],"footnotes":""},"mh-depends-on":[],"class_list":["post-80976","mhh-sticky-footer","type-mhh-sticky-footer","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DELSTRIGO-PIFELTRO - Merck Connect<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DELSTRIGO-PIFELTRO - Merck Connect\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Connect\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T07:26:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/\",\"name\":\"DELSTRIGO-PIFELTRO - Merck Connect\",\"isPartOf\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#website\"},\"datePublished\":\"2025-08-12T21:37:01+00:00\",\"dateModified\":\"2026-06-11T07:26:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.merckconnect.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DELSTRIGO-PIFELTRO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#website\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/\",\"name\":\"Merck Connect\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merckconnect.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#organization\",\"name\":\"Merck Connect\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"width\":1284,\"height\":331,\"caption\":\"Merck Connect\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DELSTRIGO-PIFELTRO - Merck Connect","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/","og_locale":"fr_CA","og_type":"article","og_title":"DELSTRIGO-PIFELTRO - Merck Connect","og_url":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/","og_site_name":"Merck Connect","article_modified_time":"2026-06-11T07:26:05+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/","url":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/","name":"DELSTRIGO-PIFELTRO - Merck Connect","isPartOf":{"@id":"https:\/\/www.merckconnect.ca\/fr\/#website"},"datePublished":"2025-08-12T21:37:01+00:00","dateModified":"2026-06-11T07:26:05+00:00","breadcrumb":{"@id":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.ca\/fr\/mhh-sticky-footer\/80976\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.merckconnect.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"DELSTRIGO-PIFELTRO"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.ca\/fr\/#website","url":"https:\/\/www.merckconnect.ca\/fr\/","name":"Merck Connect","description":"","publisher":{"@id":"https:\/\/www.merckconnect.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.merckconnect.ca\/fr\/#organization","name":"Merck Connect","url":"https:\/\/www.merckconnect.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","contentUrl":"https:\/\/www.merckconnect.ca\/fr\/wp-content\/uploads\/sites\/8\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","width":1284,"height":331,"caption":"Merck Connect"},"image":{"@id":"https:\/\/www.merckconnect.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer\/80976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer"}],"about":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/types\/mhh-sticky-footer"}],"version-history":[{"count":21,"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer\/80976\/revisions"}],"predecessor-version":[{"id":82996,"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mhh-sticky-footer\/80976\/revisions\/82996"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/media?parent=80976"}],"wp:term":[{"taxonomy":"mh-depends-on","embeddable":true,"href":"https:\/\/www.merckconnect.ca\/fr\/wp-json\/wp\/v2\/mh-depends-on?post=80976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}